



Genomic Instability and the DNA Damage Repair Response in Malignant Brain Tumors: Factors Underpinning Cancer Progression, Treatment Resistance, and Inter/Intra-Tumoral Heterogeneity

Guest Editor:

Dr. Sachin Katyal

Department of Pharmacology and Therapeutics, University of Manitoba, Research Institute in Oncology and Hematology, CancerCare Manitoba; Winnipeg, MB, Canada

Deadline for manuscript submissions:
closed (30 October 2021)

Message from the Guest Editor

Dear Colleagues,

Although comprising a small percentage (~2%) of all cancer types, malignant brain tumors affect both young and old, are often lethal, and account for a high degree of worldwide cancer mortality. Pediatric brain tumors, including gliomas and embryonal tumors, are the leading cause of cancer-related death among children and adolescents, while gliomas and meningiomas account for significant mortality in adults. Whereas precision medicine approaches are emerging, these tumors are usually treated with combinations of radiation; chemotherapy; and, more recently, immunotherapy. Recurrence of these malignant tumors is pervasive due to resistance to anticancer therapeutics, which may involve pronounced genomic instability or alteration in DNA damage repair responses elicited by chemoradiotherapy.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)